ReviewOphthalmic research2019
Pathophysiology of Diabetic Retinopathy: Contribution and Limitations of Laboratory Research.
Review in Ophthalmic research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery.International journal of molecular sciences · 2026Review
- Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.Frontiers in pharmacology · 2026Review
- Unravelling the role of natural herbs for the management of diabetes mellitus.Diabetology & metabolic syndrome · 2025Review
- Effect of ranibizumab on diabetic retinopathyWorld journal of diabetes · 2025Article
- PSCP, a novel reactive sulfur donor, activates Keap1-Nrf2 signaling and attenuates mitochondrial dysfunction in diabetic retinopathy.Frontiers in endocrinology · 2025Article
- Functional Roles of Pigment Epithelium-Derived Factor in Retinal Degenerative and Vascular Disorders: A Scoping Review.Investigative ophthalmology & visual science · 2024Article
- The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium-Glucose Transporter 2 Inhibitors.Diabetes · 2024Article
- Diabetic Retinopathy: New Treatment Approaches Targeting Redox and Immune Mechanisms.Antioxidants (Basel, Switzerland) · 2024Review
- PIK3CA regulates development of diabetes retinopathy through the PI3K/Akt/mTOR pathway.PloS one · 2024Article
- Enhanced Deep Learning Model for Classification of Retinal Optical Coherence Tomography Images.Sensors (Basel, Switzerland) · 2023Article
- Disruption of retinal inflammation and the development of diabetic retinopathy in mice by a CD40-derived peptide or mutation of CD40 in Müller cells.Diabetologia · 2022Article
- Systemic Administration of Pegylated Arginase-1 Attenuates the Progression of Diabetic Retinopathy.Cells · 2022Article
- Automated Diagnosis of Optical Coherence Tomography Angiography (OCTA) Based on Machine Learning Techniques.Sensors (Basel, Switzerland) · 2022Article
- Novel Therapeutics for Diabetic Retinopathy and Diabetic Macular Edema: A Pathophysiologic Perspective.Frontiers in physiology · 2022Review
- Sequential and Dynamic Variations of IL-6, CD18, ICAM, TNF-Disease markers · 2022Article
- Three-dimensional spheroids of choroid-retinal vascular endothelial cells as anCurrent research in pharmacology and drug discovery · 2022Article
- Wnt Signaling in Inner Blood-Retinal Barrier Maintenance.International journal of molecular sciences · 2021Review
- Insights into stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis.Neural regeneration research · 2021Article
- Article
- Deletion of Thioredoxin-Interacting Protein (TXNIP) Abrogates High Fat Diet-induced Retinal Leukostasis, Barrier Dysfunction and Microvascular Degeneration in a Mouse Obesity Model.International journal of molecular sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Preclinical models of diabetic retinopathy are indispensable in the drug discovery and development of new therapies. They are, however, imperfect facsimiles of diabetic retinopathy in humans. This chapter discusses the advantages, limitations, and physiological and pathological relevance of preclinical models of diabetic retinopathy. The judicious interpretation and extrapolation of data derived from these models to humans and a correspondingly greater emphasis placed on translational medical research in early-stage clinical trials are essential to more successfully inhibit the development and progression of diabetic retinopathy in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.